Skip to main content

Beneficial ownership — 13D / 13G

87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Redpoint Ventures IV, LLC CYN Cyngn Inc. 13G/A 3.6% 2y
EVENTIDE ASSET MANAGEMENT, LLC ANNX Annexon, Inc. 13G/A 0% 2y
ARMISTICE CAPITAL, LLC MOTS Motus GI Holdings, Inc. Common Stock 13G 9.99% 2y
ARMISTICE CAPITAL, LLC APVO Aptevo Therapeutics Inc. 13G 9.99% 2y
Granahan Investment Management, LLC MASS 908 Devices Inc. 13G 6.3% 2y
Logos Global Management LP SYRE Spyre Therapeutics, Inc. 13G/A 0.4% 2y
BOXER CAPITAL, LLC PMVP PMV Pharmaceuticals, Inc. 13G/A 0% 2y
ARMISTICE CAPITAL, LLC MRTX Mirati Therapeutics, Inc. Common Stock 13G/A 0.71% 2y
GLAZER CAPITAL, LLC VAQC Vector Acquisition Corporation II Class A Ordinary Shares 13G/A 0.08% 2y
Centiva Capital, LP DMYY dMY Squared Technology Group, Inc. 13G/A 3.15% 2y
Deep Track Capital, LP FDMT 4D Molecular Therapeutics, Inc. 13G/A 5.34% 2y
EARNEST PARTNERS LLC UFCS United Fire Group Inc 13G/A 5.1% 2y
Atalaya Capital Management LP CCAI Cascadia Acquisition Corp. Class A Common Stock 13G/A 0% 2y
Xylo Technologies Ltd. PRZO ParaZero Technologies Ltd. 13G 20.04% 2y
T. Rowe Price Investment Management, Inc. KRNY Kearny Financial Corp. 13G 10% 2y
Exor N.V. VEON VEON Ltd. 13G/A 7.6% 2y
BAKER BROS. ADVISORS LP INZY Inozyme Pharma, Inc. Common Stock 13G/A 0% 2y
PRICE T ROWE ASSOCIATES INC /MD/ IE Ivanhoe Electric Inc. 13G 6.4% 2y
Anson Funds Management LP ZVSA ZyVersa Therapeutics, Inc. 13G 9.8% 2y
T. Rowe Price Investment Management, Inc. BDTX Black Diamond Therapeutics, Inc. 13G 7.6% 2y
D1 Capital Partners L.P. LXEO Lexeo Therapeutics, Inc. 13G 9.4% 2y
Radcliffe Capital Management, L.P. INTE Integral Acquisition Corporation 1 Class A Common Stock 13G/A 0% 2y
Commodore Capital LP IMUX Immunic, Inc. 13G/A 0% 2y
PRICE T ROWE ASSOCIATES INC /MD/ CRGX CARGO Therapeutics, Inc. Common Stock 13G 5.4% 2y
Andrew Stranberg SWAG Stran & Company, Inc. 13G/A 28.7% 2y
Select Equity Group, L.P. NAPA The Duckhorn Portfolio, Inc. 13G/A 7.3% 2y
Dragoneer Investment Group, LLC CCC CCC Intelligent Solutions Holdings Inc. 13G/A 5.1% 2y
Johan Wedell-Wedellsborg YMAB Y-mAbs Therapeutics, Inc. Common Stock 13G/A 10.7% 2y
GLAZER CAPITAL, LLC BLUA BlueRiver Acquisition Corp. 13G/A 9.75% 2y
TENOR CAPITAL MANAGEMENT Co., L.P. BYNO byNordic Acquisition Corp 13G/A 0% 2y
Lundbeckfond Invest A/S LXEO Lexeo Therapeutics, Inc. 13G 6.9% 2y
Redmile Group, LLC RGNX REGENXBIO Inc. 13G/A 8.6% 2y
Forager Fund, L.P. RM Regional Management Corp. 13G/A 10% 2y
Neeraj Agrawal CXM Sprinklr, Inc. 13G/A 9.9% 2y
Matthew P. Sheehy BAER Bridger Aerospace Group Holdings, Inc. 13G 22.2% 2y
Jeff Lawson TWLO Twilio Inc 13G/A 3.8% 2y
Select Equity Group, L.P. RVTY Revvity, Inc. 13G/A 9.1% 2y
Cheshire MD Holdings, LLC MIRO Miromatrix Medical Inc. Common Stock 13G/A 0% 2y
COHEN & STEERS, INC. CUZ Cousins Properties Inc 13G/A 0% 2y
Stier Jennifer ANGI Angi Inc. 13G/A 2.9% 2y
Michael Klein SKIL Skillsoft Corp. 13G/A 12% 2y
ARMISTICE CAPITAL, LLC DRMA Dermata Therapeutics, Inc. 13G 9.99% 2y
Empyrean Capital Partners, LP CHAA Catcha Investment Corp 13G/A 0% 2y
Radcliffe Capital Management, L.P. BCSA Blockchain Coinvestors Acquisition Corp. I Class A Ordinary Shares 13G/A 0% 2y
T. Rowe Price Investment Management, Inc. ENOV Enovis CORP 13G/A 12.1% 2y
WHITEBOX ADVISORS LLC ELBM Electra Battery Materials Corp 13G/A 9.9% 2y
Advent International, L.P. FWRG First Watch Restaurant Group, Inc. 13G/A 57% 2y
T. Rowe Price Investment Management, Inc. BRKR Bruker Corp 13G/A 9.5% 2y
Deep Track Capital, LP ABOS Acumen Pharmaceuticals, Inc. 13G/A 0% 2y
Alison F. Geballe LEVI Levi Strauss & Co 13G/A 4.6% 2y